Evidence map›Paper›PMID 41146063›Full record

Observational studyBMC neurology2025

Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in France.

Sarah Wilson, Emmanuelle Leray, Floriane Calocer, Fabien Rollot, Mathieu Fauvernier, Laurent Remontet, Ludivine Launay, Sandra Vukusic, Emmanuelle Le Page, Marc Debouverie and 20 more

Abstract readObservational Study
In one paragraph

Observational study in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Sarah WilsonUNICAEN, CHU de Caen, INSERM U1086 ANTICIPE, Pôle de Recherche, Normandie University, 14000, Caen, France. sarah.wilson@unicaen.fr.
Emmanuelle LerayInserm, Arènes - UMR 6051, RSMS (Recherche Sur Les Services Et Management en Santé) - U 1309 - F-35000, Univ Rennes, EHESP, CNRS, Rennes, France.
Floriane CalocerMS Expert Center, Department of Neurology, UNICAEN, Normandie University, CHU de Caen Normandie, 14000, Caen, France.
Fabien RollotUniversité de Lyon, Université Claude Bernard, Lyon 1, Lyon, France.
Mathieu FauvernierService de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, 69000, Lyon, France.
Laurent RemontetService de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, 69000, Lyon, France.
Ludivine LaunayPlateforme MapInMed, US PLATON, Université de Caen Normandie, Centre François Baclesse, 3 Av Général Harris, 14076 Cedex, Caen, France.
Sandra VukusicUniversité de Lyon, Université Claude Bernard, Lyon 1, Lyon, France.
Emmanuelle Le PageCHU Pontchaillou, CIC1414 INSERM, F-35000, Rennes, France.
Marc DebouverieDepartment of Neurology, Nancy University Hospital, Nancy, France.
Jonathan CironDepartment of Neurology, CHU de Toulouse, CRC-SEP, 31059 Cedex 9, Toulouse, France.
Aurélie RuetUniv. Bordeaux, F-33000, Bordeaux, France.
Jérôme De SezeDepartment of Neurology and Clinical Investigation Center, CHU de Strasbourg, CIC 1434, INSERM 1434, 67000, Strasbourg, France.
Hélène ZephirCHU Lille, CRCSEP Lille, Univ Lille, U1172, F-59000, Lille, France.
Thibault MoreauDepartment of Neurology, CHU de Dijon, EA4184, 21000, Dijon, France.
David-Axel LaplaudCenter for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université, CHU Nantes, INSERM, CIC INSERM 1413, Service de Neurologie, 44000, Nantes, France.
Christine Lebrun-FrenayCentre Hospitalier Universitaire Pasteur2, Neurology, UR2CA, Université Nice Côte d'Azur, Nice, France.
Pierre ClavelouDepartment of Neurology, CHU Clermont-Ferrand, F-63000, Clermont-Ferrand, France.
Pierre LabaugeCHU de Montpellier, MS Unit, F-34295, Cedex 5, Montpellier, France.
Eric BergerCHU de Besançon, Service de Neurologie 25 030, Besançon, France.
Jean PelletierService de Neurologie, Aix Marseille Univ, APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, 13005, Marseille, France.
Olivier HeinzlefDepartement of Neurology, Hôpital de Poissy, 78300, Poissy, France.
Eric ThouvenotDepartment of Neurology, Nimes University Hospital, 30029 Cedex 9, Nimes, France.
Jean Philippe CamdessanchéDepartment of Neurology, CHU de Saint-Étienne, Hôpital Nord, 42000, Saint-Étienne, France.
Charlotte ArnaudService de Neurologie, Centre Hospitalier Universitaire de Caen Normandie, 14000, Caen, France.
Nathalie DeracheService de Neurologie, Centre Hospitalier Universitaire de Caen Normandie, 14000, Caen, France.
Pierre BrangerService de Neurologie, Centre Hospitalier Universitaire de Caen Normandie, 14000, Caen, France.
Lydia GuittetPublic Health Unit, CHU Caen Normandie, Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Caen, France.
Gilles Defer *Service de Neurologie, Centre Hospitalier Universitaire de Caen Normandie, 14000, Caen, France.
Olivier Dejardin *UNICAEN, CHU de Caen, INSERM U1086 ANTICIPE, Pôle de Recherche, Normandie University, 14000, Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccess to healthcare and socioeconomic deprivation are intricately linked. No studies have been led to measure the effect of healthcare accessibility on mortality in patients with MS so far. The objective was to examine the influence of travel time to the expert MS centre and of the accessibility to primary healthcare services on excess mortality in MS.

methodsA retrospective observational cohort study recruited patients from 18 French MS expert centres, with an onset of MS between 1960 and 2015 and a follow-up of up to 30 years. Primary health facility accessibility was measured by the Spatial aCcessibility multiscAlar index. Specialist care accessibility was measured by road travel time to the expert MS centre. Excess death rates (EDR) and excess hazard ratios were studied using additive excess hazard models with multidimensional penalised splines.

resultsThe study included 33,697 patients. Patients with relapsing-onset MS (R-MS) with a travel time of 40 min had the lowest EDR (Men: 1.2 deaths per 100 person-years (95%CI [0.8;1.8]), women: 0.8 deaths per 100 person-years 95%CI[0.6;1.2]), lower than patients who lived further from the centre. No effect of primary care access was found for patients with R-MS, and no effect of accessibility to primary or specialised care was found for patients with primary progressive MS.

conclusionThis study reveals the impact of travel time to neurologists on excess mortality in patients with R-MS in France. This distance bias association highlights the importance of preventing a potential selection of patients followed in MS expert centres.

Indexed as

CaregiversHealth Services AccessibilityMultiple SclerosisPrimary Health CareAdultCohort StudiesFemaleFranceHumansMaleMiddle AgedRetrospective StudiesExcess mortalityHealthcare accessibilityMultiple sclerosisObservational cohort studySocioeconomic status

Identifiers

PMID41146063
PMCPMC12557845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.